Related Experiment Videos

[Different forms of drug therapy for progressive sensorineural hearing loss in childhood]

A Nickisch1, M Heinemann, M Gross

  • 1Klinik für Kommunikationsstörungen, Johannes-Gutenberg-Universität Mainz.

Laryngologie, Rhinologie, Otologie
|October 1, 1988
PubMed

Insights

This study investigated a 10-day treatment for progressive sensorineural hearing loss in young patients using prednisolone, pentoxifylline, and piracetam. The combination therapy showed a 58% improvement in auditory thresholds, with no significant difference compared to previous treatments lacking piracetam.

Area of Science:

  • Otolaryngology
  • Neuroscience
  • Pharmacology

Context:

  • Progressive sensorineural hearing loss (SNHL) affects individuals across a wide age range, impacting auditory function.
  • Pediatric SNHL presents unique challenges in management and treatment efficacy.
  • Identifying effective therapeutic strategies for SNHL is crucial for preserving hearing and quality of life.

Purpose:

  • To evaluate the efficacy of a 10-day infusion treatment combining prednisolone, pentoxifylline, and piracetam in pediatric and adolescent patients with progressive sensorineural hearing loss.
  • To compare the treatment outcomes with a previous therapeutic regimen involving prednisolone and pentoxifylline, but excluding piracetam.

Summary:

  • Twenty-six patients aged 2 to 19 years with progressive SNHL received a 10-day course of intravenous prednisolone, pentoxifylline, and piracetam.
  • Auditory thresholds improved in 58% of patients following this combined therapy.
  • No statistically significant difference in treatment efficacy was observed when compared to a prior study using prednisolone and pentoxifylline without piracetam.

Impact:

  • This research contributes to understanding potential pharmacological interventions for pediatric sensorineural hearing loss.
  • The findings suggest that the addition of piracetam to prednisolone and pentoxifylline may not offer a significant advantage over the existing treatment for this condition.
  • Further research may be warranted to explore alternative or adjunctive therapies for progressive SNHL in young individuals.

Related Concept Videos